Valuation: Charles River Laboratories International, Inc.

Market Cap 10.91B 9.59B 8.91B 8.18B 15.37B 1,051B 15.61B 106B 41.36B 517B 40.97B 40.09B 1,787B P/E 2026 *
37x
P/E 2027 * 24.8x
Enterprise Value 12.73B 11.18B 10.4B 9.54B 17.92B 1,226B 18.2B 123B 48.23B 603B 47.78B 46.75B 2,083B EV / Sales 2026 *
3.31x
EV / Sales 2027 * 3.14x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
Jul. 20 Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… Zonebourse
Jul. 13 BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 MT
Jul. 13 Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating MT
Jul. 13 Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics MT
Jul. 13 Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches CI
Jul. 13 Mizuho Adjusts Price Target on Charles River Laboratories International to $230 From $192, Maintains Neutral Rating MT
Jul. 09 Morgan Stanley Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
Jul. 07 Evercore ISI Adjusts Price Target on Charles River Laboratories International to $260 From $220 MT
Jul. 01 Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing MT
Jul. 01 Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating MT
Jun. 18 Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise CI
Jun. 18 Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating MT
Jun. 17 Charles River Laboratories Shares Rise After Morgan Stanley Upgrade MT
1 day+0.96%
1 week+2.54%
Current month+1.89%
1 month+14.32%
1 week 176.12
Extreme 176.122
186.14
1 month 170.57
Extreme 170.572
189.52
Current year 146.62
Extreme 146.619
189.52
1 year 146.62
Extreme 146.619
189.52
3 years 146.62
Extreme 146.619
189.52
5 years 146.62
Extreme 146.619
189.52
10 years 146.62
Extreme 146.619
189.52
Manager TitleAgeSince
Chief Executive Officer 56 2026-05-04
Director of Finance/CFO 58 2026-04-05
Chief Tech/Sci/R&D Officer 45 2026-01-11
Director TitleAgeSince
Chairman 75 1999-12-31
Director/Board Member 56 2026-05-04
Chairman 69 2026-05-04
Change 5-day change 1-year change 3-year change Capi.($)
+0.96%+2.54% - - 10.91B
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.30%+0.83%+54.97%+107.37% 27.25B
Weighted average by Cap. +0.50%+0.91%+75.32%+136.64%

Financials

2026 *2027 *
Net sales 3.85B 3.38B 3.14B 2.88B 5.42B 371B 5.5B 37.33B 14.58B 182B 14.45B 14.14B 630B 3.92B 3.45B 3.2B 2.94B 5.52B 378B 5.61B 38.05B 14.87B 186B 14.73B 14.41B 642B
Net income 285M 250M 233M 214M 402M 27.46B 408M 2.77B 1.08B 13.5B 1.07B 1.05B 46.67B 417M 367M 341M 313M 588M 40.19B 597M 4.05B 1.58B 19.76B 1.57B 1.53B 68.31B
Net Debt 1.81B 1.59B 1.48B 1.36B 2.55B 175B 2.59B 17.59B 6.87B 85.86B 6.81B 6.66B 297B 1.39B 1.22B 1.13B 1.04B 1.95B 133B 1.98B 13.44B 5.25B 65.58B 5.2B 5.09B 227B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
26-07-24 CHF 186.14 +0.96%
26-07-23 CHF 184.36 +3.00%
26-07-22 CHF 178.99 -0.41%
26-07-21 CHF 179.74 +2.05%
26-07-20 CHF 176.12 -2.98%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
226.58USD
Average target price
230.93USD
Spread / Average Target
+1.92%

Quarterly revenue - Rate of surprise